Arbutus Biopharma Corporation (ABUS) is priced at $2.88 after the most recent trading session. At the very opening of the session, the stock price was $3.02 and reached a high price of $3.05, prior to closing the session it reached the value of $3.00. The stock touched a low price of $2.875.
Recently in News on October 13, 2020, Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference. Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection as well as therapies to treat coronaviruses (including COVID-19), today announced that the Company will participate in a virtual fireside chat at the H.C. Wainwright HBV Mini-Conference on Tuesday, October 20, 2020 at 10:00 am ET. You can read further details here
Get Ready for my next COVID-19 stock idea. I have been very fortunate in discovering biotech, therapeutic and diagnostic companies within the COVID-19 space, before wall street catches on. Our goal for our members is to get our Alert’s first before the crowd.
Arbutus Biopharma Corporation had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $9.02 on 07/24/20, with the lowest value was $0.88 for the same time period, recorded on 04/03/20.
Arbutus Biopharma Corporation (ABUS) full year performance was 226.75%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Arbutus Biopharma Corporation shares are logging -68.07% during the 52-week period from high price, and 250.62% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.82 and $9.02.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1157467 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Arbutus Biopharma Corporation (ABUS) recorded performance in the market was 3.60%, having the revenues showcasing 2.13% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 234.52M, as it employees total of 80 workers.
Specialists analysis on Arbutus Biopharma Corporation (ABUS)
During the last month, 0 analysts gave the Arbutus Biopharma Corporation a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 2.82, with a change in the price was noted +0.71. In a similar fashion, Arbutus Biopharma Corporation posted a movement of +32.72% for the period of last 100 days, recording 6,254,623 in trading volumes.
Trends and Technical analysis: Arbutus Biopharma Corporation (ABUS)
Raw Stochastic average of Arbutus Biopharma Corporation in the period of last 50 days is set at 34.34%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 5.08%. In the last 20 days, the company’s Stochastic %K was 22.60% and its Stochastic %D was recorded 33.52%.
Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 3.60%. Additionally, trading for the stock in the period of the last six months notably improved by 146.15%, alongside a boost of 226.75% for the period of the last 12 months. The shares increased approximately by -11.93% in the 7-day charts and went down by -4.95% in the period of the last 30 days. Common stock shares were driven by 2.13% during last recorded quarter.